PMID- 37760639
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20231003
IS  - 2072-6694 (Print)
IS  - 2072-6694 (Electronic)
IS  - 2072-6694 (Linking)
VI  - 15
IP  - 18
DP  - 2023 Sep 21
TI  - Outcomes of Chimeric Antigen Receptor (CAR) T-Cell Therapy in Patients with Large 
      B-Cell Lymphoma (LBCL): A Single-Institution Experience.
LID - 10.3390/cancers15184671 [doi]
LID - 4671
AB  - Chimeric antigen receptor T-cell (CAR T-cell) therapy has revolutionized the 
      treatment of relapsed/refractory (R/R) large B-cell lymphoma (LBCL). We describe 
      the real-world baseline characteristics, efficacy, safety, and post-relapse 
      outcomes of adult patients with R/R LBCL who received CAR T-cell therapy at the 
      University of California San Diego. A total of 66 patients with LBCL were treated 
      with tisagenlecleucel or axicabtagene ciloleucel. The median age was 59.5, and 
      21% were over 70 years old. Additionally, 20% of the patients had an Eastern 
      Cooperative Oncology Group (ECOG) performance score of >/=2. Cytokine release 
      syndrome incidence was 88%; immune effector cell-associated neurotoxicity 
      syndrome incidence was 56%. All-grade infection occurred in 48% of patients and 
      in 79% of patients > 70 years old. Complete response (CR) was achieved in 53% and 
      partial response in 14%. Median progression-free survival (PFS) was 10.3 months; 
      median overall survival (OS) was 28.4 months. Patients who relapsed post-CAR 
      T-cell therapy had poor outcomes, with a median OS2 of 4.8 months. Upon 
      multivariate analysis, both ECOG (HR 2.65, 95% CI: 1.30-5.41; p = 0.007) and >/=2 
      sites of extranodal involvement (HR 2.22, 95% CI: 1.15-4.31; p = 0.018) were 
      significant predictors of PFS. Twenty-six patients were R/R to CAR T-cell 
      therapy; six patients were in remission at the time of data cut off, one of whom 
      received allogeneic transplant. Overall, older patients can safely undergo CAR 
      T-cell therapy, despite the increased risk of all-grade infection. In our cohort, 
      ECOG performance score and >/=2 sites of extranodal disease are significant 
      predictors of PFS.
FAU - Trando, Aaron
AU  - Trando A
AD  - School of Medicine, University of California San Diego, La Jolla, CA 92093, USA.
FAU - Ter-Zakarian, Anna
AU  - Ter-Zakarian A
AD  - Department of Medicine, Division of Blood and Marrow Transplantation, University 
      of California San Diego, La Jolla, CA 92093, USA.
FAU - Yeung, Phillip
AU  - Yeung P
AD  - Master of Advanced Studies (MAS) Program in Clinical Research, University of 
      California San Diego, La Jolla, CA 92093, USA.
FAU - Goodman, Aaron M
AU  - Goodman AM
AD  - Department of Medicine, Division of Blood and Marrow Transplantation, University 
      of California San Diego, La Jolla, CA 92093, USA.
FAU - Hamdan, Ayad
AU  - Hamdan A
AD  - Department of Medicine, Division of Blood and Marrow Transplantation, University 
      of California San Diego, La Jolla, CA 92093, USA.
FAU - Hurley, Michael
AU  - Hurley M
AD  - Department of Medicine, Division of Blood and Marrow Transplantation, University 
      of California San Diego, La Jolla, CA 92093, USA.
FAU - Jeong, Ah-Reum
AU  - Jeong AR
AUID- ORCID: 0000-0003-2752-1554
AD  - Department of Medicine, Division of Blood and Marrow Transplantation, University 
      of California San Diego, La Jolla, CA 92093, USA.
FAU - Tzachanis, Dimitrios
AU  - Tzachanis D
AUID- ORCID: 0000-0003-4515-4428
AD  - Department of Medicine, Division of Blood and Marrow Transplantation, University 
      of California San Diego, La Jolla, CA 92093, USA.
LA  - eng
PT  - Journal Article
DEP - 20230921
PL  - Switzerland
TA  - Cancers (Basel)
JT  - Cancers
JID - 101526829
PMC - PMC10527363
OTO - NOTNLM
OT  - allogeneic hematopoietic stem cell transplant
OT  - axicabtagene ciloleucel
OT  - chimeric antigen receptor T-cell therapy
OT  - large B-cell lymphoma
OT  - tisagenlecleucel
COIS- The authors declare no conflict of interest.
EDAT- 2023/09/28 06:43
MHDA- 2023/09/28 06:44
PMCR- 2023/09/21
CRDT- 2023/09/28 01:08
PHST- 2023/07/08 00:00 [received]
PHST- 2023/09/08 00:00 [revised]
PHST- 2023/09/20 00:00 [accepted]
PHST- 2023/09/28 06:44 [medline]
PHST- 2023/09/28 06:43 [pubmed]
PHST- 2023/09/28 01:08 [entrez]
PHST- 2023/09/21 00:00 [pmc-release]
AID - cancers15184671 [pii]
AID - cancers-15-04671 [pii]
AID - 10.3390/cancers15184671 [doi]
PST - epublish
SO  - Cancers (Basel). 2023 Sep 21;15(18):4671. doi: 10.3390/cancers15184671.